ERBB2 and breast cancer: With this most recent study [91], they also verified the therapeutic efficacy of 211At-labeled NB conjugates, along with a long-lasting dosage-dependent effect following a single dose administration in a xenograft model for subcutaneous HER2+ breast cancer.